Dupixent® (dupilumab)

Covers Dupixent for its FDA‑approved indications (atopic dermatitis, asthma, CRSwNP, eosinophilic esophagitis, prurigo nodularis, COPD, chronic spontaneous urticaria, and bullous pemphigoid) and excludes non‑FDA uses. Authorization requires indication‑specific age/weight limits, documented prior therapy failures and objective diagnostics (e.g., topical steroid failure and ≥10% BSA for atopic dermatitis; blood eosinophils ≥150 cells/µL or OCS‑dependence plus controller therapy for asthma; blood eosinophils ≥300 cells/µL for COPD; ≥15 eos/HPF on biopsy for EoE), prescribing by or in consultation with the appropriate specialist, minimum treatment durations and documentation of clinical response for re‑authorization.

"Atopic dermatitis: treatment of adult and pediatric patients aged 6 months and older with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription t..."